Fosun International Leads Global Innovations in Biotechnology with Enhanced Collaboration Efforts

Fosun International Drives Global Innovations in the Pharmaceutical Sector

On November 8, 2025, Guo Guangchang, the Chairman of Fosun International, took the stage at the 3rd Pujiang Biopharmaceutical Original Innovation Conference in Shanghai. In a world where pharmaceutical innovation is increasingly under the spotlight, Guo asserted that original innovation is essential for advancement, while open cooperation can accelerate this progress.

The conference embraced the theme, "Original Innovation, the Future of Intelligent Pharmaceuticals," bringing together a diverse group of scientists, entrepreneurs, and industry representatives. Topics of discussion ranged from the current challenges in drug innovation, strategies for global cooperation, to the role of artificial intelligence (AI) in enhancing cross-industry integration.

Shanghai: A Hub of Innovation

During the conference, Guo underscored Shanghai's significance to Fosun's operations, stating, "Shanghai is not just our development hub; it's the cradle of our innovation journey." Historically, Fosun has evolved alongside Shanghai, integrating industries like Health and Intelligent Manufacturing into the city's economic fabric. Today, Fosun Pharma’s expansive global research and development network treats Shanghai as its innovation cornerstone.

Guo highlighted that Shanghai's favorable business climate fosters talent and provides a comprehensive industrial chain, allowing innovative companies to thrive. He emphasized that genuine innovation must emerge from addressing unmet clinical needs, focusing efforts on the efficacy of treatments and enhancing the patient experience.

Recent Achievements in Drug Development

Fosun has made remarkable strides in biopharmaceutical innovations this year. The company’s HANSIZHUANG, the world's first anti-PD-1 monoclonal antibody approved for small cell lung cancer treatment, has been authorized for use in nearly 40 nations, impacting over 110,000 patients globally. Notably, successful Phase III clinical trials are paving the way to a drug application for gastric cancer treatment, hinting at a shift towards chemotherapy-free options.

Fosun's extensive research and development pipeline showcases other promising products, such as HLX43, a PD-L1-targeting ADC that is currently undergoing trials in several countries. This particular drug has the potential to become a leading broad-spectrum cancer treatment.

The Role of AI in Innovation

The conference also spotlighted the transformative potential of AI in the pharmaceutical industry. Guo remarked, "Pharmaceuticals and healthcare are prime territories for AI applications, and integrating AI into our innovation processes is key to our future success." Since 2022, Fosun has been working diligently to weave AI into every aspect of drug development and operations.

With the PharmAID decision intelligence platform, Fosun has achieved significant advancements in drug-related decision-making, clinical studies, and toxicology. In healthcare services, ongoing AI applications aim to enhance diagnostic processes and patient care across an international landscape, suggesting a robust future in healthcare innovation.

Cooperative Innovation: A Fundamental Approach

Guo made it clear that innovation thrives through collaboration, stating, "It is never an isolated undertaking. It is achieved through the amalgamation of resources and collaborative capabilities.” He emphasized that strong open cooperation is essential for fostering innovation in the biopharmaceutical industry. Fosun’s efforts to deepen collaboration with global research institutions are geared towards translating academic discoveries into real-world healthcare benefits.

The company is also exploring innovative health insurance products that intertwine proactive health management with traditional insurance, highlighting collaboration with leading hospitals as a pathway for expanding trustworthy health services.

A Vision for Global Expansion

Guo stressed that globalization is crucial for Fosun, asserting that their innovative strategies must be aligned with a global vision. Their collaboration with top-tier international companies, such as establishing local manufacturing capabilities for advanced surgical products, illustrates Fosun's commitment to global integration.

Their participation in significant expos, like the China International Import Expo, points to a deliberate strategy of not just sourcing global innovations but also promoting Chinese pharmaceuticals to international markets. Overall, Henlius’ impressive cash inflow numbers from business development agreements signify robust growth opportunities ahead.

Conclusion

Looking towards the future, Guo Guangchang envisions an equally significant expansion trajectory guided by cooperative partnerships and innovative advancements in technology. Empowered by Shanghai's vibrant ecosystem, Fosun International aspires to redefine its role as a leader in the pharmaceutical arena, ensuring they meet the burgeoning healthcare needs of patients around the world.

With ongoing efforts aimed at societal health enhancements, Fosun is not just working to build a successful company—they are pursuing a mission to help people lead healthier and happier lives, exemplifying the potential of innovation in addressing global healthcare challenges.